Table 4: Adjusted OR after multivariate analysis for predictors of treatment outcome of cure.

Characteristics Cured Other treatment categories aOR (95% CI)p-value
N (%)N (%)

Cavitary lesions on CXR (N=279)
Yes45(70.3)19(29.7)1.89(1.27-2.81)0.002
No143(66.5)72(33.5)

BMI
Below 18.59(60.0)6(40.0)0.59(0.39-0.88)0.044
Above or equal 18.5199(62.8)118(37.2)

Residence
Dar105(65.2)56(34.8)1.03(0.58-1.81)0.922
Other103(60.2)68(39.8)

Positive baseline sputum culture (N=253)
Yes105(68.2)49(31.8)1.55(0.79-3.01)0.200
No62(62.6)37(37.4)

HIV status (N=208)
Yes 71(61.2) 45(38.8) 1.03(0.57-1.86) 0.933
No 137(63.4) 79(36.6)

Positive baseline sputum smear (N=253)
Yes105 (68.2)49 (31.8)0.62(0.30-1.29)0.203
No62 (62.6)37 (37.4)

Isoniazid (N=141)
Resistant87(66.9)43(33.1)1.03(0.47-2.26)0.948
susceptible7(63.6)4(36.4)

Rifampicin (N=207)
Resistant128(63.4)74(36.6)0.77(0.37-1.59)0.479
Susceptible4(80.0)1(20)

Streptomycin (N=114)
Resistant51(63.8)29(36.3) 4.67(1.53-14.32) 0.007
susceptible28(82.4)6(17.6)

Ethambutol (N=110)
Resistant50(68.5)23(31.5)0.34(0.12-0.96) 0.041
susceptible25(67.6)12(32.4)